We all know that obesity disrupts the adaptability of adipose tissue, impairing its ability to regulate energy and metabolism. Recent research published in Cell Reports1 sheds light on how PPARγ agonists, like rosiglitazone, could help restore this adaptability by reprogramming adipose progenitors.
Keep reading with a 7-day free trial
Subscribe to The Researcher Daily to keep reading this post and get 7 days of free access to the full post archives.